Recursion Obtains FDA Approval For AI-Discovered Cancer Treatment Clinical Trial
KUALA LUMPUR, Recursion announced the United States (US) Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enri…